Reports Q1 revenue $273M, consensus $225.35M. “We are off to a strong start to 2026 with outstanding revenue performance this quarter that supports raising our full-year product revenue guidance,” said Matthew Klein, CEO. “The Sephience launch continues to be strong, with sustained momentum in the US and growing momentum internationally as more countries contribute to the global launch.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Tazeen Ahmad Reiterates Buy on Strengthened Votoplam Profile and Sephience Momentum; Keeps $93 Price Target Unchanged
- PTC Therapeutics Reports Positive 24-Month Votoplam Data
- PTC Therapeutics reports ‘positive’ results from PIVOT-HD study
- PTCT Earnings this Week: How Will it Perform?
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says